Development and characterization of non-glycosylated E and NS1 mutant viruses as a potential candidate vaccine for West Nile virus.
about
West Nile Virus: biology, transmission, and human infectionVaccines in development against West Nile virusMechanism of West Nile virus neuroinvasion: a critical appraisalA Novel Synthetic TLR-4 Agonist Adjuvant Increases the Protective Response to a Clinical-Stage West Nile Virus Vaccine Antigen in Multiple FormulationsVaccine-induced protection of rhesus macaques against plasma viremia after intradermal infection with a European lineage 1 strain of West Nile virusHeterologous Protection against Asian Zika Virus Challenge in Rhesus MacaquesPlant-made vaccines against West Nile virus are potent, safe, and economically feasibleAbrogation of TLR3 inhibition by discrete amino acid changes in the C-terminal half of the West Nile virus NS1 protein.Characterization of Rabensburg virus, a flavivirus closely related to West Nile virus of the Japanese encephalitis antigenic group.Current trends in West Nile virus vaccine development.N-linked glycosylation of dengue virus NS1 protein modulates secretion, cell-surface expression, hexamer stability, and interactions with human complement.Attenuated West Nile virus mutant NS1130-132QQA/175A/207A exhibits virus-induced ultrastructural changes and accumulation of protein in the endoplasmic reticulum.Antibody-mediated neutralization of flaviviruses: a reductionist view.An inactivated cell culture Japanese encephalitis vaccine (JE-ADVAX) formulated with delta inulin adjuvant provides robust heterologous protection against West Nile encephalitis via cross-protective memory B cells and neutralizing antibodyReplication cycle and molecular biology of the West Nile virus.Vertebrate attenuated West Nile virus mutants have differing effects on vector competence in Culex tarsalis mosquitoes.Vaccines and immunotherapeutics for the prevention and treatment of infections with West Nile virus.Vaccine Mediated Protection Against Zika Virus-Induced Congenital Disease.Technologies for the development of West Nile virus vaccines.An Overview of Current Approaches Toward the Treatment and Prevention of West Nile Virus Infection.A short N-terminal peptide motif on flavivirus nonstructural protein NS1 modulates cellular targeting and immune recognition.Molecular Docking Based Screening of Plant Flavonoids as Dengue NS1 Inhibitors.Critical role of Dengue Virus NS1 protein in viral replication.Neutralization function affected by single amino acid replacement in the HIV-1 antibody targets.Virulence determinants of West Nile virus: how can these be used for vaccine design?Replication of West Nile virus, Rabensburg lineage in mammalian cells is restricted by temperature.DC-SIGN Binding Contributed by an Extra N-Linked Glycosylation on Japanese Encephalitis Virus Envelope Protein Reduces the Ability of Viral Brain InvasionA Zika virus vaccine expressing premembrane-envelope-NS1 polyproteinMosquito-borne flaviviruses: overview of viral life-cycle and host–virus interactionsChimeric yellow fever 17D-Zika virus (ChimeriVax-Zika) as a live-attenuated Zika virus vaccineRemoval of the N-Glycosylation Sequon at Position N116 Located in p27 of the Respiratory Syncytial Virus Fusion Protein Elicits Enhanced Antibody Responses after DNA Immunization
P2860
Q26865618-BECFC63C-9C13-43C9-BA18-175E5510B131Q26999702-67C5A194-BD79-4DA8-9B10-3D69D8B0EF25Q27025556-9EAAFC9F-8FAD-4716-9C6F-8F8472D6A712Q27321020-1287B3F6-73BD-4AF7-8FF7-E09174AEDC81Q27329490-91A10EC8-B87F-49A5-82D8-D3EEFC94C503Q27980556-49F1C953-B7DB-43E7-96B8-DA87D9F288B7Q28082778-554082FF-3D18-48EC-9721-DBCACC39CD3DQ33708559-3A7176C6-6198-467D-BB11-C9167F91B893Q34314429-80C4FDE0-80BC-42A2-A2F2-88517414947FQ34788758-D51A0CD9-700E-4855-AEC6-381B65D07A46Q34952610-407014E4-B11A-4A83-8E0A-D6374E30BB2AQ34990985-A7AC8D04-D913-488F-915C-17BB821E42A4Q34999617-C2C49010-A9FF-4BCD-8C76-CCDC325BBB56Q37123147-BDAC4D5E-721F-401E-9019-78B61BC6096EQ37566687-19C59723-9CF0-4037-8EC0-450EA32FB1EDQ37720871-B93899C3-AF61-43E3-AFF6-D30FC581E3E5Q37842337-6E8552C9-DC11-4B2E-8D44-6E5B192319F9Q38157833-11042FFF-7E2D-4311-ADAB-C713F0E1F9FDQ38269151-F51ABBB6-668F-4CEA-935E-85F4D7421908Q38866173-E49FA7CA-B5C4-42B4-9F36-56589AA1819FQ39686453-D9C4F052-8B34-4664-8B8C-064EAAA660D1Q40192970-FFEEFB80-38BB-40E7-A6F7-AADD028D418CQ40204571-806C95B9-745E-49FE-AF60-218AEE88105AQ41922279-2ACEB77D-03DB-478E-A85A-947771D3A806Q41935743-45661279-17C7-46DA-9911-AF9548B47AD8Q42467007-5820C767-4485-4414-A7E9-F683E83A2D39Q56000762-62084059-6977-451E-9BBF-6C9E996FA4C0Q56341869-25EFD9FA-AB92-4B57-B27A-0DDC213E22B9Q56798166-5AC857AE-6A48-4D7F-AE2D-8663FBA878C4Q57008172-7F6C42BB-4CC5-45CB-A754-7EFAD4ED6D47Q58780345-2B46D88B-42C3-49BA-99B6-E1DCA7D296C9
P2860
Development and characterization of non-glycosylated E and NS1 mutant viruses as a potential candidate vaccine for West Nile virus.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Development and characterizati ...... e vaccine for West Nile virus.
@en
type
label
Development and characterizati ...... e vaccine for West Nile virus.
@en
prefLabel
Development and characterizati ...... e vaccine for West Nile virus.
@en
P2093
P50
P1433
P1476
Development and characterizati ...... e vaccine for West Nile virus.
@en
P2093
Claire Huang
Jason A Wicker
Kyung Min Chung
Melissa C Whiteman
Richard M Kinney
P304
P356
10.1016/J.VACCINE.2009.10.112
P407
P577
2009-11-05T00:00:00Z